

## Beyond the Guidelines: Clinical Investigator Perspectives on the Management of ER-Positive Metastatic Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following adverse events is more commonly associated with abemaciclib than with palbociclib or ribociclib?
  - Alopecia
  - Anemia
  - Diarrhea
  - Fatigue
- Which of the following CDK4/6 inhibitors in combination with endocrine therapy has NOT demonstrated a significant overall survival (OS) benefit in the treatment of metastatic hormone receptor (HR)-positive breast cancer?
  - Abemaciclib
  - Palbociclib
  - Ribociclib
- The antibody-drug conjugate patritumab deruxtecan targets which of the following proteins?
  - AKT
  - HER2
  - HER3
  - TROP2
- Which of the following was the most commonly reported Grade 3 or higher adverse event among patients with ER-positive advanced breast cancer on the capivasertib/fulvestrant arm of the Phase III CAPItello-291 study?
  - Hyperglycemia
  - Hypertension
  - Rash
  - Ocular toxicities
- In the DESTINY-Breast04 study evaluating trastuzumab deruxtecan versus treatment of physician's choice for HER2-low metastatic breast cancer treated with 1 to 2 lines of chemotherapy in the metastatic setting, what was observed with trastuzumab deruxtecan among patients with HR-positive disease?
  - OS and progression-free survival (PFS) were not significantly improved
  - PFS but not OS was significantly improved
  - PFS and OS were significantly improved